Skip to main content

Table 9 The scores of SF-36 in the 12-month intervention period

From: The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design

Group

\( \overline{x}\pm S \)

t

P

The treatment group

66.87 ± 6.45

−0.781

0.435

The control group

66.55 ± 6.08